|
FMC-376 Clinical Trials
1 actively recruiting trial across 1 location
Pipeline
Phase 1/2: 1
Top Sponsors
- Frontier Medicines Corporation1
Indications
- Advanced Solid Tumors With KRAS G12C Mutations1
- KRAS G12C1
- Unresectable Solid Tumor1
- Metastatic Solid Tumor1
- Pancreatic Cancer1
La Jolla, California1 trial
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
University of California San Diego (UC San Diego) Health - Jacobs Medical Center - Moores Cancer Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.